6-K
GSK plc (GSK)
6-K
2020-06-09
For: 2020-06-09
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2020
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Ms S Jackson | |
| b) | Position/status | SVP, Global Communications & CEO Office | |
| c) | Initial<br>notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | |
| b) | Nature of the transaction | The sale of 1,209 Ordinary Shares to facilitate a transfer into an<br>ISA. | |
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) |
| £16.5557 | 1,209 | ||
| d) | Aggregated information<br><br><br><br><br><br>Aggregated volume Price | N/A (single transaction) | |
| e) | Date<br>of the transaction | 2020-06-04 | |
| f) | Place of the<br>transaction | London Stock Exchange (XLON) | |
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
| --- | --- | --- | --- |
| a) | Name | Ms S Jackson | |
| b) | Position/status | SVP, Global Communications & CEO Office | |
| c) | Initial<br>notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | |
| b) | Nature of the transaction | The purchase of 1,200 Ordinary Shares into an ISA. | |
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) |
| £16.5700 | 1,200 | ||
| d) | Aggregated information<br><br><br><br><br><br>Aggregated volume Price | N/A (single transaction) | |
| e) | Date<br>of the transaction | 2020-06-04 | |
| f) | Place of the<br>transaction | London Stock Exchange (XLON) | |
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
| --- | --- | --- | --- |
| a) | Name | Mr D Jackson | |
| b) | Position/status | PCA of Ms S Jackson (SVP, Global Communications & CEO<br>Office) | |
| c) | Initial<br>notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | |
| b) | Nature of the transaction | The sale of 1,209 Ordinary Shares to facilitate a transfer into an<br>ISA. | |
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) |
| £16.5584 | 1,209 | ||
| d) | Aggregated information<br><br><br><br><br><br>Aggregated volume Price | N/A (single transaction) | |
| e) | Date<br>of the transaction | 2020-06-04 | |
| f) | Place of the<br>transaction | London Stock Exchange (XLON) | |
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
| --- | --- | --- | --- |
| a) | Name | Mr D Jackson | |
| b) | Position/status | PCA of Ms S Jackson (SVP, Global Communications & CEO<br>Office) | |
| c) | Initial<br>notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description of the financial<br>instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB0009252882 | |
| b) | Nature of the transaction | The purchase of 1,201 Ordinary Shares into an ISA. | |
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) |
| £16.5460 | 1,201 | ||
| d) | Aggregated information<br><br><br><br><br><br>Aggregated volume Price | N/A (single transaction) | |
| e) | Date<br>of the transaction | 2020-06-04 | |
| f) | Place of the<br>transaction | London Stock Exchange (XLON) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GlaxoSmithKline plc | |
|---|---|
| (Registrant) | |
| Date: June<br>09, 2020 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GlaxoSmithKline plc |